Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer

Background:Increase of EGFR gene copy number consequent to gene amplification and/or polysomy of chromosome 7 has been significantly associated with better clinical outcome in Non Small Cell Lung Cancer (NSCLC) patients treated with Tyrosin-Kinase Inhibitors (TKIs).The primary method to detect EGFR copy number is FISH (Fluorescence in Situ Hybridization), that in lung cancer requires a precise standardization due to the presence of intratumor heterogeneity and high frequency of chromosome 7 polysomy.Recommendations and interpretative guidelines to discriminate NSCLC patients into FISH positive (gene amplification and high chromosome 7 polysomy) and FISH negative have been proposed by the University of Colorado Cancer Center (UCCC). However, in a subset of cases the distinction between EGFR amplification and chromosome 7 polysomy can be controversial because of a complex pattern of multiple EGFR and centromere signals.Methods:In order to distinguish more accurately these two genetic events, 20 NSCLC FISH positive patients, showing a controversial pattern of EGFR and centromere specific signals, were further evaluated for the status of 7q31 distal region.Results:A discrepancy between FISH results obtained with UCCC scoring system and 7q31 control was evidenced in 2 patients (10%).Conclusions:Our data strengthen the usefulness of 7q31 region evaluation to discriminate EGFR amplification from chromosome 7 polysomy in controversial EGFR FISH positive cases. Since it has been reported a possible different contribution of amplification and polysomy to TKIs susceptibility in NSCLC, the clear distinction between these two genetic events may be important to identify a subset of patients more responsive to the therapy.

source : www.diagnosticpathology.org

Related News:

• Kidney Cancer Drug Shows Promising Results
• Launch Of Ipsen’s Decapeptyl(R) 6-Month Formulation (LP 22.5 Mg) In France For The Treatment Of Prostate Cancer
• Barker Hypothesis Strengthened By Ancient Tooth Remains
• Scientists At Rice University Discover That ‘Nanobubbles’ Kill Cancer
• AM: Opioid Gains Long-Term Control of Neuropathic Cancer Pain (CME/CE)
• Launch Of Ipsen’s Decapeptyl 6-Month Formulation (LP 22.5 Mg) In France For The Treatment Of Advanced Or Metastatic Hormone-Dependent Prostate Cancer
• Green Tea Extracts Halt Growth of Prostate Cancer Tumors
• AM: Opioid Shows Long-Term Control of Neuropathic Cancer Pain (CME/CE)
• Recordati : Silodosin Approved By The European Commission For The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia
• EMEA Gives Official Scientific Advice On Clinical Phase IIb Efficacy Study Of Inecalcitol In Hormone-refractory Prostate Cancer

Details :
Submited at Wednesday, November 4th, 2009 at 7:00 am on Pathology by ethan
Comment RSS 2.0 - leave a comment - trackback